focus
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.
The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.
advertisement
Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
This gene therapy has record $4.25 million price. It's saved children.
Next article： Walensky prepares to leave CDC — and Congress — behind
Next article： Walensky prepares to leave CDC — and Congress — behind
